Phage Therapy Market Size, Share, and Trends 2025 to 2034

Phage Therapy Market (By Therapy Type: Monophage Therapy, Phage Cocktail, Engineered/Synthetic Phages, Other Phage-based Modalities; By Application: Infectious Disease Treatment, Veterinary Applications, Food Safety & Agriculture Environmental Applications, Other Applications; By Route of Administration: Oral, Topical, Injectable, Other Routes; By End-User: Hospitals & Specialty Clinics, Research Institutes & Academic Centers, Veterinary Clinics & Animal Health Providers, Other End-Users;) - Global Industry Analysis, Size, Trends, Leading Companies, Regional Outlook, and Forecast 2025 to 2034

Last Updated : October 2025  |  Report Code : 6959  |  Category : Healthcare  |  Format : PDF / PPT / Excel

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Phage Therapy Market 

5.1. COVID-19 Landscape: Phage Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Phage Therapy Market, By Therapy Type

8.1. Phage Therapy Market, by Therapy Type

8.1.1. Monophage Therapy

8.1.1.1. Market Revenue and Forecast

8.1.2. Phage Cocktail

8.1.2.1. Market Revenue and Forecast

8.1.3. Engineered/Synthetic Phages

8.1.3.1. Market Revenue and Forecast

8.1.4. Other Phage-based Modalities (e.g., Phage Lysins, Endolysins)

8.1.4.1. Market Revenue and Forecast

Chapter 9. Global Phage Therapy Market, By Application

9.1. Phage Therapy Market, by Application

9.1.1. Infectious Disease Treatment (Human Health)

9.1.1.1. Market Revenue and Forecast

9.1.2. Veterinary Applications

9.1.2.1. Market Revenue and Forecast

9.1.3. Food Safety & Agriculture

9.1.3.1. Market Revenue and Forecast

9.1.4. Environmental Applications (Wastewater, Bioremediation, etc.)

9.1.4.1. Market Revenue and Forecast

9.1.5. Other Applications (Microbiome Modulation, Diagnostics, etc.)

9.1.5.1. Market Revenue and Forecast

Chapter 10. Global Phage Therapy Market, By Route of Administration 

10.1. Phage Therapy Market, by Route of Administration

10.1.1. Oral

10.1.1.1. Market Revenue and Forecast

10.1.2. Topical

10.1.2.1. Market Revenue and Forecast

10.1.3. Injectable

10.1.3.1. Market Revenue and Forecast

10.1.4. Other Routes (Inhalation, Nasal, etc.)

10.1.4.1. Market Revenue and Forecast

Chapter 11. Global Phage Therapy Market, By End-User 

11.1. Phage Therapy Market, by End-User

11.1.1. Hospitals & Specialty Clinics

11.1.1.1. Market Revenue and Forecast

11.1.2. Research Institutes & Academic Centers

11.1.2.1. Market Revenue and Forecast

11.1.3. Veterinary Clinics & Animal Health Providers

11.1.3.1. Market Revenue and Forecast

11.1.4. Other End-Users (Food Safety Agencies, Environmental Bodies, etc.)

11.1.4.1. Market Revenue and Forecast

Chapter 12. Global Phage Therapy Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Therapy Type

12.1.2. Market Revenue and Forecast, by Application

12.1.3. Market Revenue and Forecast, by Route of Administration

12.1.4. Market Revenue and Forecast, by End-User

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Therapy Type

12.1.5.2. Market Revenue and Forecast, by Application

12.1.5.3. Market Revenue and Forecast, by Route of Administration

12.1.5.4. Market Revenue and Forecast, by End-User

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Therapy Type

12.1.6.2. Market Revenue and Forecast, by Application

12.1.6.3. Market Revenue and Forecast, by Route of Administration

12.1.6.4. Market Revenue and Forecast, by End-User

12.2. Europe

12.2.1. Market Revenue and Forecast, by Therapy Type

12.2.2. Market Revenue and Forecast, by Application

12.2.3. Market Revenue and Forecast, by Route of Administration

12.2.4. Market Revenue and Forecast, by End-User

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Therapy Type

12.2.5.2. Market Revenue and Forecast, by Application

12.2.5.3. Market Revenue and Forecast, by Route of Administration

12.2.5.4. Market Revenue and Forecast, by End-User

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Therapy Type

12.2.6.2. Market Revenue and Forecast, by Application

12.2.6.3. Market Revenue and Forecast, by Route of Administration

12.2.6.4. Market Revenue and Forecast, by End-User

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Therapy Type

12.2.7.2. Market Revenue and Forecast, by Application

12.2.7.3. Market Revenue and Forecast, by Route of Administration

12.2.7.4. Market Revenue and Forecast, by End-User

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Therapy Type

12.2.8.2. Market Revenue and Forecast, by Application

12.2.8.3. Market Revenue and Forecast, by Route of Administration

12.2.8.4. Market Revenue and Forecast, by End-User

12.3. APAC

12.3.1. Market Revenue and Forecast, by Therapy Type

12.3.2. Market Revenue and Forecast, by Application

12.3.3. Market Revenue and Forecast, by Route of Administration

12.3.4. Market Revenue and Forecast, by End-User

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Therapy Type

12.3.5.2. Market Revenue and Forecast, by Application

12.3.5.3. Market Revenue and Forecast, by Route of Administration

12.3.5.4. Market Revenue and Forecast, by End-User

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Therapy Type

12.3.6.2. Market Revenue and Forecast, by Application

12.3.6.3. Market Revenue and Forecast, by Route of Administration

12.3.6.4. Market Revenue and Forecast, by End-User

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Therapy Type

12.3.7.2. Market Revenue and Forecast, by Application

12.3.7.3. Market Revenue and Forecast, by Route of Administration

12.3.7.4. Market Revenue and Forecast, by End-User

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Therapy Type

12.3.8.2. Market Revenue and Forecast, by Application

12.3.8.3. Market Revenue and Forecast, by Route of Administration

12.3.8.4. Market Revenue and Forecast, by End-User

12.4. MEA

12.4.1. Market Revenue and Forecast, by Therapy Type

12.4.2. Market Revenue and Forecast, by Application

12.4.3. Market Revenue and Forecast, by Route of Administration

12.4.4. Market Revenue and Forecast, by End-User

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Therapy Type

12.4.5.2. Market Revenue and Forecast, by Application

12.4.5.3. Market Revenue and Forecast, by Route of Administration

12.4.5.4. Market Revenue and Forecast, by End-User

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Therapy Type

12.4.6.2. Market Revenue and Forecast, by Application

12.4.6.3. Market Revenue and Forecast, by Route of Administration

12.4.6.4. Market Revenue and Forecast, by End-User

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Therapy Type

12.4.7.2. Market Revenue and Forecast, by Application

12.4.7.3. Market Revenue and Forecast, by Route of Administration

12.4.7.4. Market Revenue and Forecast, by End-User

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Therapy Type

12.4.8.2. Market Revenue and Forecast, by Application

12.4.8.3. Market Revenue and Forecast, by Route of Administration

12.4.8.4. Market Revenue and Forecast, by End-User

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Therapy Type

12.5.2. Market Revenue and Forecast, by Application

12.5.3. Market Revenue and Forecast, by Route of Administration

12.5.4. Market Revenue and Forecast, by End-User

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Therapy Type

12.5.5.2. Market Revenue and Forecast, by Application

12.5.5.3. Market Revenue and Forecast, by Route of Administration

12.5.5.4. Market Revenue and Forecast, by End-User

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Therapy Type

12.5.6.2. Market Revenue and Forecast, by Application

12.5.6.3. Market Revenue and Forecast, by Route of Administration

12.5.6.4. Market Revenue and Forecast, by End-User

Chapter 13. Company Profiles

13.1. Micreos B.V.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Eliava Biopreparations Ltd. (Eliava Institute, Georgia)

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. PhagePro Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. EnBiotix, Inc. (Merged with Armata Pharmaceuticals)

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Technophage SA

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Fixed-Phage Ltd.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. iNtODEWORLD (South Korea)

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Proteon Pharmaceuticals S.A.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Phagelux Inc.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. AmpliPhi Biosciences

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The phage therapy market size is expected to increase from USD 1.24 billion in 2024 to USD 1.85 billion by 2034.

The phage therapy market is expected to grow at a compound annual growth rate (CAGR) of around 4.08% from 2025 to 2034.

The major players in the phage therapy market include Micreos B.V., Eliava Biopreparations Ltd., PhagePro Inc., EnBiotix, Inc., Technophage SA, Fixed-Phage Ltd., iNtODEWORLD, Proteon Pharmaceuticals S.A., Phagelux Inc., and AmpliPhi Biosciences.

The driving factors of the phage therapy market are the increasing global crisis of antibiotic resistance and the rising demand for precision antimicrobial solutions.

North America region will lead the global phage therapy market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client